DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Chapman PB, Hauschild A, Robert C et al.
Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor vemurafenib with dacarbazine (DTIC) in patients with V600EBRAF-mutated melanoma.
ASCO Annual Meeting Plenary Session including Science of Oncology Award and Lecture. 2011
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.